Home / Pharmaceutical / The Pharmaceutical Market: Taiwan

The Pharmaceutical Market: Taiwan

Published: Dec 2014 | No Of Pages: 139 | Published By: Espicom

Product Synopsis

OVERVIEW OF THE PHARMACEUTICAL MARKET IN TAIWAN
 
We continue to view Taiwan as a challenging market for multinationals, mostly on account of the difficult pricing and reimbursement environment, which is due to undergo further changes. Specifically, as part of the Second Generation National Health Insurance (NHI) programme, which becomes effective in 2013, a new reimbursement system is expected to be rolled out in Taiwan. The American Chamber of Commerce in Taipei (AmCham), in its latest White Paper published in 2012, wrote that it hoped that the new system - known as the Drug Reimbursement Item and Payment Scheme (DRIPS) - will not become so complicated as to cause delays in patient access to innovative new drugs.
 
Headline Expenditure Projections
  • Pharmaceuticals: TWD135.10bn (US$4.59bn) in 2011 to TWD140.44bn (US$4.71bn) in 2012; +4.2% in local currency terms and +2.6% in US dollar terms. US dollar forecastback in the positive territory, unlike inQ412, on account of exchange rate fluctuations.
  • Healthcare: TWD953.29bn (US$32.42bn) in 2011 to TWD1,018bn (US$34.15bn) in 2012; +6.5% in local currency terms and +5.3% in US dollar terms. Local currency forecastslightly up sinceQ412, on account of macroeconomic factors.
  • Medical devices: TWD52.63bn (US$1.79bn) in 2011 to TWD55.09bn (US$1.85bn) in 2012; +4.7% in local currency terms and +4.3% in US dollar terms. Local currency forecastslightly up sinceQ412, on account of macroeconomic factors.
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT10
Political12
Economic13
Business Environment14
Industry Forecast15
Pharmaceutical Market Forecast15
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Taiwan 2010-2018)17
 
Healthcare Market Forecast18
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2010-2018)20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2010-2018)21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2010-2018)21
 
Presciption Drug Market Forecast21
 
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Taiwan 2010-2018)23
 
Patented Drug Market Forecast24
 
Table: Top 10 Pharmaceuticals In Taiwan According To BNHI Expenditure During 200825
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Taiwan 2010-2018)26
 
Generic Drug Forecast26
 
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Taiwan 2010-2018)29
 
OTC Medicine Market Forecast29
 
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Taiwan 2010-2018)32
 
Pharmaceutical Trade Forecast32
 
Table: Pharmaceutical Trade Data And Forecasts (Taiwan 2012-2018)35
Table: Pharmaceutical Trade Data And Forecasts local currency (Taiwan 2012-2018)35
 
Other Healthcare Data35
Key Risks To BMI's Forecast Scenario37
Macroeconomic Forecasts39
 
Table: Taiwan - Economic Activity41
 
Industry Risk Reward Ratings42
Asia Risk/Reward Ratings42
Taiwan Risk/Reward Ratings48
Rewards48
Risks48
Market Overview50
Industry Trends And Developments51
Epidemiology51
Healthcare System53
Healthcare Insurance54
 
Table: Sources Of Financing55
 
Healthcare Financing56
 
Table: Taiwan Insurance Coverage57
 
Medical Tourism58
Traditional Chinese Medicine59
Biotechnology Sector60
Vaccines63
Clinical Trials65
Regulatory Development70
 
Table: Medicine Categories In Taiwan71
Table: Examples Of Controlled Drugs In Taiwan72
 
Recent Regulatory Developments72
Intellectual Property Regime74
Pricing Regime78
Reimbursement Regime80
 
Table: Reimbursement System in Taiwan80
Table: Drug Reimbursement Principles82
Table: BNHI Spending By Type Of Outpatient Claims, As Percentage Of Total83
 
Competitive Landscape87
Pharmaceutical Industry87
 
Table: Western & TCM Manufacturers, 2006-1087
Table: Pharmaceutical Output Value by Type, 2002-2010 (US$mn)88
 
Domestic Pharmaceutical Sector88
 
Table: Top-20 Pharmaceutical & Biotechnology Firms In Taiwan According To Market Capitalisation (US$mn)88
Table: TGPA Members, 201290
 
Foreign Pharmaceutical Sector93
 
Table: Corporate Members Of Taiwan's IRPMA, 201294
 
Pharmaceutical Wholesale97
 
Table: Western Drug Distributors 2006-201097
 
Pharmaceutical Retail98
 
Table: Pharmacies, 2006-201098
 
Company Profile100
Yung Shin Pharmaceutical (YSP)100
ScinoPharm Taiwan103
Empax Pharma108
TaiGen110
Pfizer113
Sanofi116
GlaxoSmithKline (GSK)118
Novartis121
Merck & Co124
Demographic Forecast126
 
Table: Taiwan's Population By Age Group, 1990-2020 ('000)127
Table: Taiwan's Population By Age Group, 1990-2020 (% Of Total)128
Table: Taiwan's Key Population Ratios, 1990-2020129
 
Glossary130
Methodology132
Pharmaceutical Expenditure Forecast Model132
Healthcare Expenditure Forecast Model132
Notes On Methodology133
Risk/Reward Ratings Methodology134
Ratings Overview135
 
Table: Pharmaceutical Risk/Reward Ratings Indicators135
 
Indicator Weightings136
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +